SOBREPIN

SOBREPIN AEROSOL "40 MG/3 ML SOLUTION FOR NEBULIZER" 10 SINGLE-DOSE CONTAINERS OF 3 ML"

SOBREPIN AEROSOL "40 MG/3 ML SOLUTION FOR NEBULIZER" 10 SINGLE-DOSE CONTAINERS OF 3 ML"

Skip to product information
1 of 0
  • Secure payment
  • Discreet and sanitized package
  • Fast and safe shipping

Description

Name
SOBREPIN AEROSOL 40 mg/3 ml nebulising solution
Sobrerolo


What is it and what is it used for?
The active ingredient in Sobrefluid is sobrerol, a mucolytic.
This medicine is indicated to facilitate the removal of excess mucus in acute and chronic respiratory tract conditions.

Contact your doctor if you do not feel better or if you feel worse after 3 days.


What you need to know before taking the medicine
Do not use SOBREPIN AEROSOL
- if you are allergic to sobrerol or any of the other ingredients of this medicine (listed in section 6);
- if you are pregnant or breastfeeding. (see "Pregnancy and breastfeeding");
- in children under 30 months;
- in children with a history of epilepsy or febrile seizures.


Warnings and precautions
Talk to your doctor or pharmacist before using SOBREPIN AEROSOL.
Pay particular attention:
This medicine contains sobrerol which, in excessive doses, can induce neurological disorders such as convulsions in infants and children.

Do not prolong treatment for more than 3 days due to the risks associated with the accumulation of terpene derivatives in the body, including the brain, and in particular the risks of neuropsychological disorders.

Do not administer doses higher than those recommended to avoid a greater risk of adverse drug reactions and disorders associated with overdose.

Children
The product should not be used in children under 30 months of age, as mucolytics can cause bronchial occlusion (the ability to clear bronchial mucus in children under 30 months is limited due to the characteristics of their airways).


Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.

Side effects with unknown frequency (frequency cannot be estimated from the available data):
- allergic (hypersensitivity) reactions manifested by itching, skin rash, urticaria, edema and dyspnea;
- bronchial obstruction (temporary narrowing of the upper airways);
- gastric (stomach) disorders;
- nausea.

Reporting of side effects
If you experience any side effects, including any not listed in this leaflet, talk to your doctor or pharmacist. You can also report side effects directly via the national reporting system at: https://www.aifa.gov.it/content/segnalazionireazioni-avverse .
By reporting side effects you can help provide more information on the safety of this medicine.

SOBREPIN

SOBREPIN AEROSOL "40 MG/3 ML SOLUTION FOR NEBULIZER" 10 SINGLE-DOSE CONTAINERS OF 3 ML"

SOBREPIN AEROSOL "40 MG/3 ML SOLUTION FOR NEBULIZER" 10 SINGLE-DOSE CONTAINERS OF 3 ML"

MINSAN code: 038403034
Previous price: €12,03
Regular price €12,50
Regular price €0,00 Sale price €12,50
-% Sold out
Tax included. Shipping calculated at checkout.
View full details

Product images are purely indicative and may not be fully representative of the packaging and product features, as they may vary in color, size, or content. Any decorations, gift wrapping, and items included in the images for product presentation purposes will not be shipped with orders. Product names, ingredients, and percentages indicated in the descriptions are purely indicative and may be subject to change or updates by the manufacturers. Due to the impossibility of updating these updates in real time, the photos and technical information of the products listed on farmaInnovation.it may differ from those shown on the label or otherwise disclosed by the manufacturers. The only identifying element is the MINSAN (Ministry of Health) code. Farmacia Barni, farmainnovation.it , does not guarantee the accuracy and timeliness of the information published and declines all responsibility for any errors, omissions, or failure to update it. farmainnovation.it assumes no responsibility for damages of any kind that may arise from accessing the published information.